uniQure (NASDAQ:QURE) Reaches New 1-Year High – Still a Buy?

uniQure (NASDAQ:QURE) hit a new 52-week high during trading on Monday . The stock traded as high as $17.95 and last traded at $17.71, with a volume of 450937 shares traded. The stock had previously closed at $16.98.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Stifel Nicolaus lifted their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

The company has a market capitalization of $854.95 million, a P/E ratio of -3.54 and a beta of 0.89. The firm’s fifty day moving average is $8.13 and its 200 day moving average is $6.78. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. As a group, analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP acquired a new stake in shares of uniQure in the 3rd quarter worth $49,000. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $53,000. Quarry LP purchased a new stake in uniQure in the third quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.